(Total Views: 205)
Posted On: 07/19/2023 5:14:33 PM
Post# of 231
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its entry into definitive agreements with health care-focused institutional investors. The agreements are for the sale and issuance of 7,425,744 shares of the company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $0.885 per share, exercisable at the date of issuance and expiring five years following the issuance date. Subject to the satisfaction of customary conditions, the closing of the offering is expected to occur on or about July 21, 2023. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its entry into definitive agreements with health care-focused institutional investors. The agreements are for the sale and issuance of 7,425,744 shares of the company’s common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $0.885 per share, exercisable at the date of issuance and expiring five years following the issuance date. Subject to the satisfaction of customary conditions, the closing of the offering is expected to occur on or about July 21, 2023. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
